Our Covalent Inhibitors Library comprises 12,000 unique molecules containing at least one covalent warhead. It has a great potential for covalent inhibitor design, and now it is translated into a ready-to-be-docked format for users to kick-start their covalent ligand project.

Reaxense launches its internal drug discovery program named e-BioModular™ Pseudokinases Research Platform.

A joint FEBS / Biochemical Society Focused Meeting Exploring Kinomes: Pseudokinases and Beyond will be held on 24-26 March 2013 Robinson College, Cambridge, UK.